Latest financial market updates and expert analysis
Analysis A failed cholesterol trial at Novartis did more damage to BioNTech’s share price last week than anything coming out of Mainz. That disconnect says plenty about how biotech sentiment currently...
BioNTech is quietly negotiating the sale of a substantial chunk of the manufacturing network it assembled during the pandemic. The...
There aren’t many companies that can draw 31 million viewers to a 26-minute gameplay video and still watch their share...
The numbers are staggering by any standard. A 133.7 percent gain in 30 days. A stock trading 524 percent above...
The arithmetic at BYD is becoming hard to reconcile. On one side of the ledger sits an overseas sales machine...
The electrolyser maker has spent the summer stacking up operational wins — a first commercial hydrogen delivery in Germany, a...
The arithmetic of Novo Nordisk’s share repurchase is straightforward: since 4 February, the Danish drugmaker has bought back 32,034,179 B-shares...
The full extent of Radiant Uranium Corp.’s Athabasca Basin footprint has only now come into view. Alongside the two exploration...
The brickmaker’s shareholders have spent the past month digesting a steady drip of corporate developments, yet the stock’s trajectory tells...
The consultation machinery of South African labour law is now grinding into motion at Sibanye-Stillwater’s Kwezi shaft, where management has...
The gap between what Primary Hydrogen is building and what its share price is saying has rarely been wider. Over...
